Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV

25. januar 2008 opdateret af: University of Valencia

Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients.

The rapidly progression of the disease in HIV-HCV co-infected patients justify the treatment.

Combination of Peg interferon and Ribavirin is the best treatment because it improve the compliance of treatment.

In APRICOT study genotypes 2 and 3 patients received 48 weeks and the rates of end of treatment response was 64% and the sustained virological response (24 weeks after the end of treatment) 62%.

In mono-infected patients trials showed there are not differences in the sustained virological response between 24 and 48 weeks of treatment, however exit the doubt concerning the different kinetic viral in HIV-HCV co-infected patients and this could be related with a lost of profit with a shorter duration of treatment, only 24 weeks.

In this study we woud like to evaluate if 24 weeks of treatment in HIV-HCV co-infected patients genotype 2 or 3 will have the same rate of clearance of virus at the end of follow-up period.

Studieoversigt

Status

Ukendt

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Patients will randomized to receive 180 µg/weekly of Pef interferon alpha-2a and 800 mg/daily of Ribavirin during 24 weeks or 48 weeks.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

59

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Spanien
      • Alicante, Spanien, 03010
        • Hospital General de Alicante
      • Barcelona, Spanien, 08003
        • Hospital del Mar
      • Castellón, Spanien, 12004
        • Hospital General de Castellon
      • Granada, Spanien, 18013
        • Hospital Clínico San Cecilio
      • Huelva, Spanien, 21004
        • Hospital Infanta Elena
      • Madrid, Spanien, 28040
        • Hospital Clinico San Carlos
      • Madrid, Spanien, 28046
        • Hospital La Paz
      • Murcia, Spanien, 3003
        • Hospital General de Murcia
      • Málaga, Spanien, 29010
        • Hospital Carlos Haya
      • Sevilla, Spanien, 41008
        • Hospital Virgen Macarena
      • Valencia, Spanien, 46015
        • Hospital Arnau de Vilanova
      • Valencia, Spanien, 46009
        • Hospital La Fe
      • Valencia, Spanien, 46014
        • Hospital General Universitario de Valencia
    • Alicante
      • Elche, Alicante, Spanien, 03202
        • Hospital de Elche
    • Barcelona
      • Badalona, Barcelona, Spanien, 08915
        • Hospital Germans Trias i Pujol
    • Cádiz
      • Jerez de la Frontera, Cádiz, Spanien, 11009
        • Hospital de Jerez
    • Pontevedra
      • Vigo, Pontevedra, Spanien, 36204
        • Hospital Xeral-Cíes
    • Valencia
      • Gandia, Valencia, Spanien, 46700
        • Hospital de Gandia

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Male and female patients of 18-65 years of age
  • Serologic evidence of chronic hepatitis C infection by detectable plasma HCV-RNA
  • Serologic evidence of HIV-1 infection by ELISA and Western-blot
  • Stable status of HIV-1 infection in the opinion of the investigator
  • Negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug. Additionally, all fertile males and females must be using two forms of effective contraception during treatment and during the 6 months after treatment end. This may include, but is not limited to, using birth control pills, IUDs, condoms, diaphragms, or implants, being surgically sterilized, or being in a post-menopausal state.
  • Willingness to give written informed consent and willingness to participate to and comply with the study

Exclusion Criteria:

  • Women with ongoing pregnancy or breast feeding
  • IFN or ribavirin therapy at any previous time
  • Any investigational drug <6 weeks prior to the first dose of study drug
  • History or other evidence of a medical condition associated with chronic liver disease other than HCV
  • Hepatocarcinoma observed
  • History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease
  • Active HIV-related opportunistic infection and/or malignancy requiring acute systemic therapy
  • Absolute neutrophil count <1500 cells/mm3
  • Hgb <12 g/dL in women or 13 g/dL in men or any patient for whom anemia would be medically problematic
  • Hemoglobinopathy (e.g. thalassemia) or any other cause of or tendency for hemolysis
  • Platelet count <90000 cells/mm3
  • Serum creatinine level >1.5 times the upper limit of normal at screening
  • History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer at therapeutic doses for major depression or psychosis, respectively, for at least 3 months at any previous time or any history of the following: a suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease
  • History of a severe seizure disorder or current anticonvulsant use
  • History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis)
  • History or other evidence of chronic pulmonary disease associated with functional limitation
  • History of significant cardiac disease that could be worsened by acute anemia
  • History of thyroid disease poorly controlled on prescribed medications. Patients with elevated thyroid stimulating hormone (TSH) concentrations with elevation of antibodies to thyroid peroxidase and any clinical manifestations of thyroid disease are excluded
  • Evidence of severe retinopathy
  • History of major organ transplantation with an existing functional graft
  • History or other evidence of severe illness, malignancy or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
  • History of any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) <6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study
  • Drug use within 6 months of 1st dose and excessive alcohol consumption

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: 1
Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 24 weeks
Medicin: Peg interferon + Ribavirin
Peg interferon 180 mcg/weekly Ribavirin 800 mg/daily during 24 weeks
Andre navne:
  • Pegasys
Medicin: Peg interferon + Ribavirin
Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
Andre navne:
  • Pegasys
Aktiv komparator: 2
Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
Medicin: Peg interferon + Ribavirin
Peg interferon 180 mcg/weekly Ribavirin 800 mg/daily during 24 weeks
Andre navne:
  • Pegasys
Medicin: Peg interferon + Ribavirin
Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
Andre navne:
  • Pegasys

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
% of patients with RNA-HCV undetectable 24 weeks
Tidsramme: 24 weeks after the end of treatment
24 weeks after the end of treatment

Sekundære resultatmål

Resultatmål
Tidsramme
% of patients at the end of treatment
Tidsramme: 48 weeks of treatmemt
48 weeks of treatmemt

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

University of Valencia

Samarbejdspartnere

Hoffmann-La Roche

Efterforskere

  • Studieleder: Enrique Ortega, Dr, Hospital General Universitario de Valencia

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. november 2005

Primær færdiggørelse (Forventet)

1. april 2008

Studieafslutning (Forventet)

1. december 2008

Datoer for studieregistrering

Først indsendt

25. januar 2008

Først indsendt, der opfyldte QC-kriterier

25. januar 2008

Først opslået (Skøn)

11. februar 2008

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

11. februar 2008

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

25. januar 2008

Sidst verificeret

1. januar 2008

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • KHRONOS
  • 2005-000203-34

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner